We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cardiac Marker POC Tests Now Widely Used in Hospitals

By LabMedica International staff writers
Posted on 04 Jan 2010
Cardiac marker point-of-care (POC) tests are now widely used in hospitals and have emerged as a successful model of the concept of point-of-care diagnostics, according to a new market report.

The 2008 world market for POC cardiac enzymes and tests is estimated at US$490 million, and growing at 12% a year for the past three years, according to healthcare market research publisher Kalorama Information (New York, NY, USA). More...
Cardiac markers are specific enzymes or proteins that tend to be concentrated when a cardiac event is likely to occur. Brain natriuretic peptide (BNP), CK-MB (creatine kinase, muscle and brain [subunits]), myoglobin, and troponin I/T are the most commonly tested markers. Testing for these markers can effectively indicate when intervention is or is not necessary. Lab-based tests can take up to 24 hours, which has driven demand for the point-of-care products that can deliver "stat” results.

"After many years of tests to prove effectiveness, there has been the stark realization that cardiac markers are useful to rule out or rule in the variety of cardiovascular conditions that are present in an ER [emergency room],” said Shara Rosen, the report's author.

The leaders in the cardiac enzyme POC market are Inverness's (Waltham, MA, USA) Triage, Siemens Healthcare's (Erlangen, Germany) Stratus, and Roche's (Nutley, NJ, USA) POC systems (Accutrend Plus, Roche Cardiac 200, Cobas h232). Of all POC testing that occurs in hospitals, cardiac marker tests are the fastest growing segment. Also at least another 20 companies market test strips for all or one of the marker panels. These companies' rapid tests help physicians triage cardiac patients more quickly.

Point-of-care or decentralized testing has long been the standard of care for glucose, but in other areas, results have been mixed. Products have been utilized, but never in the numbers that were predicted when the technologies were developed. The growth of cardiac markers is one part of a significant trend towards the use of POC tests, which now represent 15 percent of all tests conducted in hospitals.

POC testing has expanded because of studies that demonstrate the clinical effectiveness of these tests and technologic advancements that have increased their accuracy. Kalorama's research looked at the current state of glucose testing, as well as other emerging POC test categories, including the fast growing infectious disease and cholesterol test segments.

Kalorama Information supplies independent market research in the life sciences, as well as a full range of custom research services.

Related Links:

Kalorama Information




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.